ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Clinical trials for ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy boosts standard chemo to wipe out hidden leukemia cells
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps eliminate leftover cancer cells in adults newly diagnosed with acute myeloid leukemia (AML). About 49 participants receive either chemo alone or chemo plus pembrolizumab. The goal …
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:26 UTC
-
Immunotherapy boosts standard AML treatment in older patients
Disease control OngoingThis study tests whether adding an immunotherapy drug (pembrolizumab) to standard treatment (azacitidine and venetoclax) helps older adults with acute myeloid leukemia (AML) achieve deeper remission and lower the chance of the cancer returning. About 60 participants who are not e…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:25 UTC
-
New chemo combo aims to keep leukemia from returning after transplant
Disease control OngoingThis study tests whether giving two chemotherapy drugs, clofarabine and melphalan, before a donor stem cell transplant can help prevent leukemia or myelodysplasia from coming back. The trial includes 72 adults whose cancer is in remission or who have high-risk myelodysplastic syn…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 02:18 UTC
-
New hope for younger AML patients: targeted chemo combo shows promise
Disease control OngoingThis study tests a chemotherapy drug called CPX-351 in people under 60 who have a type of leukemia that developed from a previous blood disorder or cancer treatment. The goal is to see how well the drug can stop the cancer from growing and achieve remission. About 21 participants…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Could a targeted drug boost chemo for tough blood cancers?
Disease control OngoingThis study tests whether adding the experimental drug veliparib to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. About 25 adults took part. The goal was to see…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New combo therapy shows promise in early trial for aggressive blood cancer
Disease control OngoingThis early-phase trial tests a new drug called navtemadlin (KRT-232) combined with standard chemotherapy (cytarabine and idarubicin) in 24 adults with newly diagnosed acute myeloid leukemia (AML). The goal is to find the safest dose and see if the combination can better control t…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New drug combo shows promise against tough leukemia
Disease control OngoingThis study tests a new drug called pevonedistat alongside standard chemotherapy (cytarabine and idarubicin) in people newly diagnosed with high-risk acute myeloid leukemia (AML). The goal is to find the best dose and see if the combination improves the chance of complete remissio…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New antibody takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-stage study tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The main goals are to find the safest dose and check for side effects. The drug works by targeting a protein on cancer cells to stop …
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New drug combo shows promise for blood cancers in early trial
Disease control OngoingThis study tested a combination of two drugs, vorinostat and azacitidine, in 135 people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find the safest dose and see how well the drugs work together to stop cancer cell growth. Participants rece…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
New combo therapy shows promise for tough blood cancers
Disease control OngoingThis study tests a combination of two chemotherapy drugs (CPX-351) plus a targeted antibody (gemtuzumab ozogamicin) in about 50 adults whose acute myeloid leukemia or high-risk myelodysplastic syndrome has returned or not responded to prior treatment. The goal is to see if the co…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
Targeted drug shows promise for Hard-to-Treat blood cancers with IDH mutation
Disease control OngoingThis study tests a drug called olaparib in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has returned or not responded to treatment and who have a specific change in the IDH gene. The drug works by blocking enzymes that cancer cells need to grow. The…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
Talking therapy fights fatigue in blood cancer patients
Symptom relief OngoingThis study looks at whether cognitive behavioral therapy (CBT) can help people with acute myeloid leukemia or lymphoma who feel very tired from their cancer or treatment. About 48 patients will take part in up to 7 counseling sessions to learn new ways to cope with fatigue. The g…
Matched conditions: ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 17, 2026 02:21 UTC